Abstract:Half-sandwich pseudo-octahedral pentamethylcyclopentadienyl IrIII complexes of the type [(η5-Cpx)Ir(C^C)Cl]PF6, where Cpx is pentamethylcyclopentadienyl (Cp*), or its phenyl (Cpxph = C5Me4C6H5) or biphenyl (Cpxbiph = C5Me4C6H4C6H5) derivatives, and the C^C-chelating ligands are different N-heterocyclic carbene (NHC) ligands, have been synthesized and characterized. Three X-ray crystal structures have been determined. Except for Cp* complex 1A, the other eleven complexes 1B-4C all showed potent cytotoxicity, with IC50 values ranging from 2.9 to 46.3 μM toward HeLa human cervical cancer cells. The potency toward HeLa cells increased with additional phenyl substitution on Cp*: Cpxbiph > Cpxph > Cp*, and increased with the size of chain substitution on the C^C-ligand in the order: ph > butyl > ethyl > methyl. Complex [(η5-C5Me4C6H4C6H5)Ir(L4)Cl]PF6 (4C) displayed the highest potency, and was about 3 times more active than the clinical platinum drug cisplatin. Complexes 1A-4C all undergo hydrolysis and their kinetics was studied. DNA binding appears not to be the major mechanism of action. The ability of these iridium complexes to catalyze hydride transfer from the coenzyme NADH to NAD+ was studied. Complexes [(η5-C5Me4C6H4C6H5)Ir(L2)Cl]PF6 (2C) and [(η5-C5Me4C6H4C6H5)Ir(L3)Cl]PF6 (3C) cause cell apoptosis and arrest the cell cycle at the G1 phase and G2/M phase when HeLa cancer cells are treated with different IC50 concentrations of the complexes, and increase the amount of reactive oxygen species (ROS) dramatically, which appears to contribute to the anticancer activity. This class of organometallic Ir complexes has unusual features worthy of further exploration in the design of novel anticancer drugs.

Design and anticancer behaviour of cationic/neutral half-sandwich iridium(III) imidazole-phenanthroline/phenanthrene complexes

Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents

Half-sandwich Iridium N-heterocyclic Carbene Anticancer Complexes

Preparation and Bioactivity of Iridium(III) Phenanthroline Complexes with Halide Ions and Pyridine Leaving Groups

Iminoamido chelated iridium(III) and ruthenium(II) anticancer complexes with mitochondria-targeting ability and potential to overcome cisplatin resistance

Cationic N,S-chelate Half-Sandwich Iridium Complexes: Synthesis, Characterization, Anticancer and Antiplasmodial Activity.

Increasing Anticancer Activity with Phosphine Ligation in Zwitterionic Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes

Effects of structurally varied fluorescent half-sandwich iridium(III) Schiff base complexes on A549 cell line

Mitochondrial Targeting Half-Sandwich Iridium(iii) and Ruthenium(ii) Dppf Complexes and in Vitro Anticancer Assay

Synthesis, Subcellular Localization and Anticancer Mechanism Studies of Unsymmetrical Iridium(III) Complexes

In Vitro and In Vivo of Triphenylamine-Appended Fluorescent Half-Sandwich Iridium(III) Thiosemicarbazones Antitumor Complexes

Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp 2 -N/sp 3 -N Donor Ligands to Achieve Improved Anticancer Selectivity

In Vitro and In Vivo Antitumor Assay of Mitochondrially Targeted Fluorescent Half-Sandwich Iridium(III) Pyridine Complexes

Cytotoxic and Apoptosis-Inducing Activities of Iridium Complexes Bearing 2-Phenylimidazo[4,5-f][1,10]-Phenanthroline Derivatives in Human Cancer Cells

Anticancer effect evaluation of iridium(III) complexes targeting mitochondria and endoplasmic reticulum.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Preparation and antitumor application of N -phenylcarbazole/triphenylamine-modified fluorescent half-sandwich iridium( iii ) Schiff base complexes

Design, synthesis, and antitumor mechanism investigation of iridium(III) complexes conjugated with ibuprofen

Triphenylamine-Appended Half-Sandwich Iridium(III) Complexes and Their Biological Applications.

Lysosomal Targeted Cyclometallic Iridium(III) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Synthesis, Characterization and Anticancer Efficacy Studies of Iridium (III) Polypyridyl Complexes against Colon Cancer HCT116 Cells